These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32839127)

  • 1. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
    Jammah AA
    Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M; Gu W; Chen L; Li Y; Kuang H; Du J; Alvarez A; Lauand F; Souhami E; Zhang J; Xu W; Du Q; Mu Y;
    Diabetes Obes Metab; 2024 Sep; 26(9):3791-3800. PubMed ID: 38922731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
    Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
    Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
    Davidson JA; Desouza C; Fonseca V; Frias JP; Van Gaal L; Giorgino F; Chao J; Dex TA; Roberts M; Saremi A; Leiter LA
    Diabet Med; 2020 Feb; 37(2):256-266. PubMed ID: 31365765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
    Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
    J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.
    Home PD; Mehta R; Hafidh KAS; Gurova OY; Alvarez A; Serafini P; Pourrahmat MM
    Diabetes Obes Metab; 2021 Dec; 23(12):2660-2669. PubMed ID: 34402153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
    Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
    Kumar S; Jang HC; Demirağ NG; Skjøth TV; Endahl L; Bode B
    Diabet Med; 2017 Feb; 34(2):180-188. PubMed ID: 27027878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
    Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
    Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
    Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
    Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
    Ritzel R; Ghosh S; Emral R; Malek R; Zeng L; Mabunay MA; Landgraf W; Guyot P; Serafini P; Pushkarna D; Malik RA
    Diabetes Obes Metab; 2023 Sep; 25(9):2495-2504. PubMed ID: 37312665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
    Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
    J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
    Giorgino F; Caruso I; Napoli R
    Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.